U.S., April 1 -- ClinicalTrials.gov registry received information related to the study (NCT07503613) titled 'Long Term Follow-up Study of AAVAnc80-antiVEGF Gene Therapy' on March 26.
Brief Summary: This multi-center, observational, post-intervention LTFU study will monitor for safety and efficacy of AAVAnc80- antiVEGF in individuals with vestibular schwannoma who have previously received an intracochlear administration of AAVAnc80-antiVEGF in an interventional clinical trial
Study Start Date: March, 2026
Study Type: OBSERVATIONAL
Condition:
Vestibular Schwannoma
Recruitment Status: ENROLLING_BY_INVITATION
Sponsor: Akouos, Inc.
Published by HT Digital Content Services with permission from Health Daily Digest....